Abstract Between 5% and 10% of all breast cancer is hereditary, with patients having a
strong family history of the disease. The remaining 90-95% of cases are classed as …

Multiple guidelines exist for the follow-up of breast cancer, with no agreement on frequency
or duration. The contribution of routine clinical examination for the detection of potentially …

EGFr/HER1 and c‐erbB‐2/HER2 expression are associated with poor prognosis in breast
cancer. The type I receptor tyrosine kinase (RTK) family to which they belong has four …

Regular clinical follow up after breast cancer is a common practice. Evidence from
retrospective reviews casts doubt on the efficacy of this practice and the various guidelines …

Abstract The development of Herceptin (Trazumatab) makes testing for HER2 status
important for choosing optimal therapy in breast cancer. This study addresses the precision …

Abstract ERBB4/HER4 (referred to here as ERBB4) is a unique member of the epidermal
growth factor receptor (EGFR) family of receptor tyrosine kinases. In contrast to the other …

Current studies of tumor angiogenesis rely on the concept that endothelium proliferates 30–
40 times faster in tumors than in normal tissues. This evidence is based on histological …

Purpose: Chromogenic in situ hybridization (CISH) is a new modification of the fluorescence
in situ hybridization (FISH) technique for detection of oncogene amplification in archival …

PURPOSE: To assess the potential of Doppler perfusion index (DPI) measurement as a
routine diagnostic tool in the detection of occult colorectal liver metastases. MATERIALS …

Background We have shown previously that whilst overexpression of HER1, 2 and 3 is
associated with poor prognosis in breast cancer, HER4 is associated with a good prognosis …